Cisplatin increases urinary sodium excretion in rats: gender-related differences.
OBJECTIVE. There are well-documented reports of cisplatin-associated hyponatremia in the literature, but there are no data on gender-dependent differences. The aim of the present study was to define characteristics of 24-hour urinary sodium excretion in young adult Wistar rats of both genders and to evaluate the gender-related effect of cisplatin. MATERIALS AND METHODS. Twelve control Wistar rats (6 males and 6 females) and 12 cisplatin-treated Wistar rats (6 males and 6 females) after a single and repeated injection of cisplatin (once a day for 3 days) at a dose of 2.5 mg/kg body weight into the caudal vein were examined. The experiment was carried out by measuring 24-h urinary sodium, potassium, chloride, magnesium, creatinine excretion and pH in the urine of age-matched male and female rats. RESULTS. The 24-h urinary sodium excretion, sodium/chloride ratio, and diuresis showed no gender-related differences in control rats. After a single administration of 2.5 mg/kg cisplatin, 24-h urinary sodium excretion was not significantly higher in cisplatin-treated rats than in gender-matched controls. After repeated cisplatin administration, 24-h urinary sodium excretion was significantly higher in cisplatin-treated male rats as compared to matched controls (P<0.05). No such effect was found in cisplatin-treated female rats. CONCLUSION. The study data show that cisplatin enhances urinary sodium excretion in male but not in female rats. The mechanism of such a gender-related effect is not yet clear. Further investigations are necessary to elucidate the mechanism of this pharmacological effect of cisplatin.
Institute of Oncology, Vilnius University, Vilnius, Lithuania. donatasstakisaitis@vvkt.lt
Donatas
D
Stakisaitis
Giedre
G
Dudeniene
Rimas Jonas
RJ
Jankūnas
Grazina
G
Grazeliene
Janina
J
Didziapetriene
Birute
B
Pundziene
D000367:Age Factors; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002151:Calorimetry; D002712:Chlorides / Q000652:urine; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003627:Data Interpretation, Statistical; D004231:Diuresis; D005260:Female; D007010:Hyponatremia / Q000139:chemically induced*; D008297:Male; D010783:Photometry; D051381:Rats; D017208:Rats, Wistar; D012737:Sex Factors; D012964:Sodium / Q000652:urine*; D013997:Time Factors
D000970:Antineoplastic Agents; D002712:Chlorides; D012964:Sodium; D002945:Cisplatin